Gofen & Glossberg’s ResMed RMD Stock Holding History

Gofen & Glossberg’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-893	Closed	-$217K	–	597
2022 Q1	$217K	Sell	893 -31	-3%	-$7.5K	﹤0.01%	535
2021 Q4	$241K	Buy	924 +6	+0.7%	+$1.56K	0.01%	518
2021 Q3	$242K	Hold	918	–	–	0.01%	500
2021 Q2	$226K	Buy	+918	New	+$193K	0.01%	506
2020 Q3	–	Sell	-1,256	Closed	-$241K	–	483
2020 Q2	$241K	Buy	+1,256	New	+$205K	0.01%	388

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Gofen & Glossberg's RMD Position: Q2 2022 in Review

Gofen & Glossberg sold out of ResMed (RMD) in Q2 2022, closing a stake of 893 shares — an estimated $217K sold.

Gofen & Glossberg first reported a position in RMD in Q2 2020 and held it in 5 quarters. The position peaked at $242K in Q3 2021. 676 funds tracked by Wall St. Rank hold RMD as of Q2 2022.

Gofen & Glossberg reported no remaining ResMed position as of Q2 2022 after selling out during the quarter.
Gofen & Glossberg sold 893 ResMed shares in Q2 2022, an estimated $217K.
Gofen & Glossberg first reported a position in ResMed in Q2 2020 and held it in 5 quarters.
Gofen & Glossberg's ResMed position peaked at $242K in Q3 2021.
676 funds tracked by Wall St. Rank held ResMed as of Q2 2022.

Based on Gofen & Glossberg's 13F filing for Q2 2022, filed 14 Jul 2022.